TrialBlood advances2021

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.

Charlotte M Niemeyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.